Is Zimmer Biomet’s Q4 Beat And 2026 Guidance Altering The Investment Case For ZBH?

NodeGuardian

2026-03-17 06:29:19

Abstract generation in progress

Zimmer Biomet Holdings reported strong Q4 2025 results, beating analyst expectations with adjusted earnings per share of US$2.42 and net sales of US$2.24 billion. The company also provided optimistic guidance for 2026, forecasting 2.5% to 4.5% revenue growth and adjusted earnings per share of US$8.30 to US$8.45. This performance supports the investment narrative around steady demand for orthopedic procedures and the company’s ability to leverage its portfolio and robotics investments, though risks like pricing pressure and acquisition integration still exist.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.